Patient Report Outcome and Oncological Safety -Oncoplastic and Conventional BCS Cohort

NCT ID: NCT05054777

Last Updated: 2021-09-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

5000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-01

Study Completion Date

2024-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Breast-conserving surgery (BCS) is the traditional surgical treatment for early-stage breast cancer patients. There are evidences indicating that oncoplastic BCS could improve cosmetic outcomes and/or quality of life, and has similar oncological safety as conventional BCS does. However, these studies that focused on patient-reported outcomes and oncological safety were mainly from one institution or of small sample size. The variations across hospitals and regions were not fully analyzed. A multicenter prospective patient report outcome (PROs) and oncological safety will be planned to assess the PROs and safety for Chinese breast cancer patients who will undergo oncoplastic and conventional breast-conserving surgery (OBCS). This study follows the Helsinki Declaration and Chinese rules. All patients will be asked to sign the informed consent and will be followed up 24 months after operations. All data will be collected.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patient Reported Outcome Oncological Safety Breast-conserving Surgery Breast Cancer Female

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

oncoplastic breast-conserving surgery

The oncoplastic breast-conserving surgery were mainly those surgeries using volume displacement or volume replacement techniques

oncoplastic breast-conserving surgery

Intervention Type PROCEDURE

The patients received oncoplastic breast-conserving surgery, including volume displacement or volume replacement techniques

conventional breast-conserving surgery

The conventional breast-conserving surgery were performed without any oncoplastic operations

conventional breast-conserving surgery

Intervention Type PROCEDURE

conventional breast-conserving surgery without any oncoplastic operations

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

oncoplastic breast-conserving surgery

The patients received oncoplastic breast-conserving surgery, including volume displacement or volume replacement techniques

Intervention Type PROCEDURE

conventional breast-conserving surgery

conventional breast-conserving surgery without any oncoplastic operations

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Informed consent signed;
2. Non-metastatic Breast cancer patients confirmed by pathology;
3. Adult (\>18 years old, \<80 years old);
4. Female;
5. Must undergo oncoplastic or conventional breast-conserving surgery;

Exclusion Criteria

1. Inflammatory breast cancer, Stage IV breast cancer patients;
2. Have other malignant tumors;
3. Pregnancy women;
4. Have severe co-morbidities that compromise the patients' compliance to our protocol, or endanger the patients;
5. Refuse breast-conserving surgery.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shandong Cancer Hospital and Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zhiyong Yu

PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chao Li, MD

Role: CONTACT

008615665851082

Zhiyong Yu, PhD

Role: CONTACT

008613355312277

References

Explore related publications, articles, or registry entries linked to this study.

Weber WP, Soysal SD, Fulco I, Barandun M, Babst D, Kalbermatten D, Schaefer DJ, Oertli D, Kappos EA, Haug M. Standardization of oncoplastic breast conserving surgery. Eur J Surg Oncol. 2017 Jul;43(7):1236-1243. doi: 10.1016/j.ejso.2017.01.006. Epub 2017 Jan 31.

Reference Type BACKGROUND
PMID: 28214053 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ShandongCHI-18

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.